Home Latest Articles
Latest Articles
  • Buzukela Abuduaini, Jiyuan ZHANG, Yunlin SONG
    World Clinical Drug. 2024, 45(3): 333-337.

    Sepsis is a systemic inflammatory response syndrome induced by infection, and the pathophysiological changes are accompanied by metabolic disorders and abnormal inflammatory responses. However, the clinical characteristics and related molecular mechanisms of inflammation-metabolic reprogramming are still unclear. Recent studies have reported that dichloroacetate (DCA) can reverse the metabolic reprogramming secondary to sepsis, participate in cell metabolism, mitochondrial function, oxidative stress response, glucose and lipid metabolism, protein metabolism, and immune regulation, but the possible mechanism of action has not been fully clarified. To further study the effects of DCA on sepsis, this article reviewed the current application of DCA in sepsis and its possible molecular mechanisms, providing new targets, new ideas, and new methods for the prevention and treatment of sepsis.

  • Fanxin ZENG, Kesi WANG
    World Clinical Drug. 2024, 45(3): 338-340.

    Selective estrogen receptor degrader (SERD) is commonly used in the endocrine therapy of estrogen receptor (ER) positive advanced breast cancer. Elacestrant is a novel oral SERD that is for the treatment of advanced breast cancer with ER-positive and human epidermal growth factor receptor (HER)2-negative. It is more effective than other endocrine therapies and can significantly improve the median progression free survival of patients, and is also effective for breast cancer patients with ER gene α mutations. The launch of elacestrant will provide a more effective treatment option for patients with ER-positive, HER2-negative advanced breast cancer.

  • Qingli DING, Bo GONG
    World Clinical Drug. 2024, 45(3): 341-344.

    Through national negotiations on innovative drugs and the update of drug catalogue, more and more effective therapeutic drugs have been included in the medical insurance fund, which reduces the burden of medical expense while meeting the drug needs of insured patients. However, some violations of laws and regulations of clinical drug use in the supervision of medical insurance fund have been found. At the same time, with the implementation of new policies such as centralized drug procurement policy, "dual channel drugs" and reform of medical insurance payment methods, as well as the development of new medical forms such as "internet+health care", some new problems and phenomena have also been found in the supervision. Based on the typical cases in the supervision of medical insurance, this paper summarized the common violations of clinical drug use.

  • Lingwei MA, Yuanyuan FENG, Xinmeng SUN, Zhiyong WU, Wei ZHANG, Hexia XIA
    World Clinical Drug. 2024, 45(2): 107-111.

    With the failure of ovarian function, the function of other important organs is also gradually decreased. Some perimenopausal women experience physical, mental symptoms or illnesses, which affect their quality of life. Menopausal hormone therapy (MHT) improves and alleviates the symptoms caused by decline or even failure of ovarian function by adding exogenous sex hormones. This paper reviewed the application scope, commonly regimens and the risks and benefits of various sex hormones, including progestogens, estrogens, combined estrogen-progestogens preparations in MHT, in order to provide a reference for drug use in perimenopausal women.

  • Junmin LI, Jialei ZHU, Jing TANG
    World Clinical Drug. 2024, 45(2): 112-118.

    The onset of endometrial cancer and atypical endometrial hyperplasia is gradually becoming younger, and the current childbearing age is generally delayed, which makes these patients have a great demand for fertility sparing treatment. As the second most common gynecological malignancy in China, the standard treatment is total hysterectomy and bilateral adnexectomy, which leads to permanent infertility. Progesterone is effective in the treatment of early-stage endometrial cancer and atypical endometrial hyperplasia without destroying fertility. Screening criteria for these patients have been recommended in guidelines. Oral megestrol acetate and medroxyprogesterone acetate are the most commonly used fertility sparing treatments, levonorgestrel-releasing intrauterine devices, as a local progesterone therapy, can not be ignored. In addition, studies on the combination of progesterone drugs with metformin and gonadotropin releasing hormone agonist are being carried out. Facing the limitations of existing treatment options, it is equally important to actively search for therapeutic and prognostic markers, and explore new treatment methods.

  • Hui ZHAO, Mingming YAN, Qian ZHANG, Xiaoyan QIU, Mingkang ZHONG
    World Clinical Drug. 2024, 45(2): 119-127.
    Objective

    To investigate the association between testosterone replacement therapy (TRT) and serious adverse events, based on the FDA adverse event reporting system (FAERS) database.

    Method

    Reporting odds ratio (ROR) and Bayesian confidence propagation neural network were applied to analyze the adverse reaction reports in FAERS database from January 2004 to June 2023.

    Result

    A total of 16 702 testosterone users were included according to the including/excluding criteria, and 424 pharmacovigilance signal were detected, among which 155 were strong signals, referring to 29 system organ classes, such as cardiovascular, reproductive, nervous and endocrine systems. The most significant adverse events including polycythemia [ROR 149.10, 95%CI 128.65—172.80, lower limit of information component (IC025) 6.05], testis atrophy (ROR 114.47, 95%CI 89.88—145.79, IC025 4.92), clear cell renal cell carcinoma (ROR 86.97, 95%CI 64.47—117.32, IC025 4.23), and acute myocardial infarction (ROR 20.40, 95%CI 18.77—22.17, IC025 4.14).

    Conclusion

    The serious adverse reactions associated with TRT were mainly thrombosis, serious cardiovascular events and tumor risk, which significantly increased the mortality and disability rate. Health care workers should pay more attention to the potential risk of TRT-related erious adverse events and balance the benefits and risks.

  • Yifan LI, Anni WANG, Xin FENG
    World Clinical Drug. 2024, 45(2): 128-132.
    Objective

    To explore the safety warning signals of dienogest in the FDA adverse event reporting system (FAERS) and to provide reference for clinical safe drug use.

    Methods

    The reports related to dienogest collected from the FAERS database from the first quarter of 2004 to the first quarter of 2022 were searched for adverse event signals by using the reporting odds ratio method in disproportionality analysis. The term set of the International Dictionary of Medical Terms was used for sinicization and analysis.

    Results

    The number of adverse event reports with dienogest as the primary suspect drug was 790 reports with 66 signals. The safety signals were pulmonary embolism after operation, cerebellar stroke, mixed anxiety and depression disorder, Steele's disease and venous embolism. It mainly involves vascular and lymphatic diseases, respiratory system, chest and mediastinal diseases, various injuries, poisoning and operational complications.

    Conclusion

    The FAERS database can be used to comprehensively analyze and study the adverse events of dienogest after marketing, and provide a basis for safe and rational clinical drug use. When using dienogest in clinic, we should pay close attention to the vascular and lymphatic diseases of the drug, and take intervention measures as soon as possible to ensure the safe and effective use of the drug.

  • Yongyi XIE, Xin MA, Junwen ZENG, Xiaoxiang XU, Dan DENG, Yeqiang LIU
    World Clinical Drug. 2024, 45(2): 133-138.
    Objective

    To explore the establishment of a human-derived xenograft mouse model for giant congenital melanocytic nevus (GCMN).

    Methods

    Skin from GCMN patients was transplanted onto the backs of two mice with severe combined immunodeficiency, which were then removed after 4 weeks of pressure bandaging. The survival and histopathological characteristics of the transplanted GCMN skin were observed.

    Results

    Mouse No.1 died at 1 week after operation, which may be related to overlarge graft area. Mouse No.2 survived for a long time. The skin xenograft was stable for at least 28 weeks. There was no scar formation at the junction of grafted skin and normal mouse skin. HE staining at GCMN site showed that there were epithelioid nevus cells and melanin granules in the dermis, and immunohistochemistry showed that melanin antigen, microphthalmia transcription factor, S-100 protein, Sry-related HMG-BOX gene 10 were all positive.

    Conclusion

    The human-derived xenograft mouse model of GCMN constructed by this method can maintain the histological features and important molecular phenotypes of GCMN. Meanwhile, the transplanted skin can survive for a long time, which can be used for subsequent basic experiments, and is conducive to the further investigation of the pathogenesis of GCMN and its potential drug development.

  • Xiaona TONG, Ruixiang CHEN, Li GUI, Wei CHEN
    World Clinical Drug. 2024, 45(2): 139-146.
    Objective

    To investigate the effects of flavonoids from moringa oleifera leaf on lipid metabolism in HepG2 cells and its potential mechanism.

    Methods

    HepG2 cell model with lipid deposition was constructed, and the cells were treated with moringa leaf flavonoids (final concentration 1, 2, 5, 10μg/ml). Cell counting kit (CCK-8) assay was used to detect cell viability. Oil red O staining was used to detect intracellular lipid droplet staining. The expression of reactive oxygen species (ROS) and adenosine triphosphate (ATP) were detected by the kit. The expression of lipid metabolism-related genes [low-density lipoprotein receptor (LDLR), sterol regulatory component binding protein-1C (SREBP-1C), caveolin-1 (CAV1) and acetyl coenzyme a acetyltransferase 1 (ACAT1)] were detected by quantitative real time polymerase chain reaction. The expression levels of nuclearfactor-E2-relatedfactor (Nrf) 2/hemeoxygenase (HO)-1 signaling pathway were detected by western blot.

    Results

    The cells treated with 1, 2, 5μg/ml of moringa leaf flavonoids were selected for the experiment. Compared with model group, the levels of ROS, SREBP-1c and ACAT1 in HepG2 cells in moringa leaf flavonoids treatment group were significantly decreased, while the levels of ATP, LDLR, CAV1 and Nrf2 and HO-1 protein expressions were significantly increased in a dose-dependent manner, with statistically significant differences (P<0.05). Inhibition of Nrf2/HO-1 signaling pathway reversed the regulatory effect of moringa leaf flavonoids on lipid metabolism related genes expression.

    Conclusion

    Moringa oleifera leaf flavonoids can improve oxidative stress and lipid metabolism in lipid-deposited HepG2 cells, possibly through activation of Nrf2/HO-1 signaling pathway.

  • Aimin ZHU, Xiaohong XU, Qiuxiang CHEN, Xia MI, Ce ZHANG, Chi ZHANG
    World Clinical Drug. 2024, 45(2): 147-152.
    Objective

    To explore the effect of roxadustat on anemia and cardiac function in patients with maintenance peritoneal dialysis (MPD).

    Methods

    A total of 90 patients with renal anemia receiving MPD who were regularly followed up for at least 3 months in the Peritoneal Dialysis Center of our hospital from January 2019 to December 2022 were selected and divided into control group and observation group, with 45 cases in each group. The control group was given subcutaneous injection of erythropoietin, and the observation group was given oral roxadustat capsule for 16 weeks. Anemia indexes [red blood cell (RBC), hemoglobin (Hb), hematocrit (Hct)], iron metabolism indexes [transferrin (TRF), total iron binding capacity (TIBC), serum iron, serum ferritin (SF), hepcidin (Hepc)], and cardiac function indexes [brain natriuretic peptide (BNP), left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD)] were collected and compared.

    Results

    After treatment, RBC, Hb and Hct in both groups were significantly improved compared with before treatment (P<0.05), and anemia indexes in observation group were higher than those in the control group (P<0.05). The levels of TRF, TIBC, serum iron and SF in the observation group were higher than those in the control group (P<0.05), and the level of Hepc in the observation group was lower than that in the control group (P<0.05). Compared with control group, BNP level in observation group was significantly decreased (P<0.05). LVEDD and LVESD decreased in the observation group, but the difference was not statistically significant (P>0.05).

    Conclusion

    Roxadustat can obviously improve anemia in MPD patients, and has a certain effect on cardiac function.

News